Several studies have indicated that disease-specific impairments and treatment-specific side-effects in prostate cancer patients involve mainly urinary and bowel symptoms and decreased sexual function (Schover, 1993) . In a previous retrospective study of men with localised prostate cancer who had undergone external beam radiation therapy we found a significant decrease in all aspects of the sexual function after treatment. Moreover, a majority of the men who experienced a diminished sexual function were also distressed by this (Helgason et al., 1995) . Other existing data have indicated that distress due to sexual and/or urinary and bowel symptoms may be common among prostrate cancer patients (Berger et al., 1993; Pedersen et al., 1993; Brasilis et al., 1995; Litwin et al., 1995).
Several studies have indicated that disease-specific impairments and treatment-specific side-effects in prostate cancer patients involve mainly urinary and bowel symptoms and decreased sexual function (Schover, 1993) . In a previous retrospective study of men with localised prostate cancer who had undergone external beam radiation therapy we found a significant decrease in all aspects of the sexual function after treatment. Moreover, a majority of the men who experienced a diminished sexual function were also distressed by this (Helgason et al., 1995) . Other existing data have indicated that distress due to sexual and/or urinary and bowel symptoms may be common among prostrate cancer patients (Berger et al., 1993; Pedersen et al., 1993; Brasilis et al., 1995; Litwin et al., 1995) .
An attempt to investigate the willingness of a non-prostate cancer population, in the same age group as prostate cancer patients, to trade off life expectancy for an intact sexual function indicated that a majority of men were willing to do this (Singer et al., 1991) . However, the number of men surveyed was small and the study was not population based, precluding a generalisation to the general population.
The primary aim of the present study was to identify and quantify the most important disease-specific distress for prostate cancer patients. We also wanted to measure the prevalence of the relevant symptoms in a reference population without prostate cancer and assess the willingness to trade off long-term survival for an intact sexual function.
Materials and methods
In October 1993, we identified all 450 men who were alive and had been diagnosed with prostate cancer in 1992 in the area of Stockholm, Sweden, and who were 50-80 years of age at the time. An equal number of men were randomly selected from the same geographical region to gain reference data. The reference group was frequency matched to have a similar age distribution as men with newly detected prostate cancer. The random selection was possible as all Swedish citizens have an individual civic registration number and are included in a population registry. We excluded all men not born in Sweden or dead at time of identification, leaving 431 patients and 435 men in the reference group. The study was approved by the regional ethics committee.
After a letter of introduction, the men in both groups were sent a questionnaire including 'The Radiumhemmets Scale of Sexual Function' and questions assessing urinary and bowel functions. Questions concerning concurrent disease and prescribed medication were also incorporated. The prostate cancer patients were asked which treatment or treatments they had been subjected to for their prostate cancer. The questionnaire was confidential and the men indicated that they had returned it on an identification form that was returned separately from the completed questionnaire. To assess the representativeness of the reference group, the prevalence of diabetes mellitus and myocardial infarction was compared with available official statistics for the prevalence of these two conditions in Swedish men (Statistics, Sweden, 1996) , using indirect age standardisation. Information regarding the prevalence of prostate cancer in 50 to 80-year-old men in the Stockholm region, was retrieved from the local cancer registry. A ratio of proportions was calculated with a 95% confidence interval based on the method proposed by Mantel and Haenszel (Rothman, 1986) . For a comparison between two proportions, a P-value was calculated using Fisher's exact test (Rothman, 1986) . A two-sided P-value below 0.05 was considered statistically significant.
Results
The questionnaire was returned by 73% of men in the reference group and 79% of the prostrate cancer patients (Table I) . Reasons for non-response are presented in Table I . Five men in the randomly selected group reported that they had prostate cancer and were excluded from further analysis, leaving 314 men in the reference group. The median age of responding men with and without prostate cancer was 72 years (range 51-80 years) and 68 years (range 50-80 years) respectively (Table II) . Of the men with prostate cancer, 109 had received endocrine treatment, 22 had been subjected to radical prostatectomy only, 37 had been irradiated only, 35 reported endocrine treatment subsequent to radical surgery or radiotherapy and 139 men had not received any of these treatments at the time of investigation.
Compared with the reference group, a larger proportion of the prostate cancer patients reported low frequency of sexual functions (less than once a month) in all aspects of sexuality assessed in this study, the ratio of proportions (with 95% confidence interval) being 2.0 (1.6-2.4) for sexual desires, 2.3 (1.9-2.8) for sexually stimulated erections, 1.6 (1.4-1.8) for intercourse and 2.1 (1.8-2.5) for orgasm. All differences between the groups were statistically significant (P <0.05) (not in table). Any decrease in sexual function as compared with youth is presented in Table III. A majority of the men in both groups reported they were troubled by a diminished sexual function compared with youth (Table IV) , and many stated that this distressed them severely ( Figure 1 ). There was no significant difference between the prostate cancer patients and the reference group with regard to the proportion of men reporting distress due to waning sexual function when all degrees of distress were taken into account. The prostate cancer patients were, however, significantly more likely to be distressed (the highest category on a five-category ordinal scale) because of a waning sexual function (P< 0.05) with a ratio of proportions (with 95% confidence interval) of 1.5 (1.1-2.2) for sexual desire, 1.3 (1.0-1.6) for erection capacity, 1.5 (1.2-1.9) for orgasm pleasure and 2.1 (1.4-3.0) for ejaculate volume (not in table) .
Compared with men in the reference group, men with prostate cancer reported a significantly higher incidence of 'physiological impotence' (P<0.001) with a ratio of proportions (with 95% confidence interval) of 2.3 (1.9-2.7). There was no statistically significant difference between the 'physiologically impotent' men in the prostate cancer group vs the reference group with regards to the extent to which they were distressed by their erectile dysfunction. The relative risk being 0.9(0.8-1.2). (not in table) .
Of the men in the reference group, 299 answered the question regarding the willingness to trade off the possibility of longer life expectancy for an intact sexual function if the curative effect of available treatment was uncertain (Table V) . Of these men, 62% stated they were willing to make this trade-off. Moreover, 19% were not willing to risk their sexual function even if it was proven that the treatment prolonged life, given that they had 80% chance of being alive after 10 years without any curative treatment. On the other hand, 38% of the men in the reference group would choose treatment irrespective of eventual effects on their sexual function. There was no difference in the willingness, or unwillingness, for a trade-off in various age groups (Table V) . Of the 25 men with prostate cancer included in the pilot study, 22 answered the question and 63% stated that they were willing to trade off the possibility of longer life for an intact sexual function (not in table). Urinary and bowel symptoms were less common than a decline in sexual function in both the men with and without prostate cancer (Table III) . Among the urinary and bowel symptoms, a weak urinary stream was most common in both groups (Table III) but few men were troubled by it (Table IV and Figure 2 ). Of the urinary and bowel symptoms, distress due to urinary urgency was the most frequent in both groups (Table IV and Figure 2 ). Of the men subjected to radical surgery, many reported a urinary leakage (Table III) and one-third appeared to be troubled by this (Table IV) but only 4% of the men reporting urinary leakage stated that they were severely distressed (not in Table) . Of all men, few stated that they were severely distressed by urinary or bowel symptoms (Figure 2) .
Of those reporting any complication, the prostate cancer patients reporting urinary leakage, weak urinary stream and bowel urgency were significantly more likely to be distressed by this than were the men in the reference group reporting similar symptoms, the ratio of proportions (with 95% confidence interval) being 2.0 (1.1-3.6), 2.2 (1.3-3.6) and 1.8 (1.0-3.4) (not in Table) . There was no significant difference between the groups with regard to distress caused (Pedersen et al., 1993; Brasilis et al., 1995; Helgason et al., 1995; Litwin ct al., 1995 Patients subjected to radical surgery or radiotherapy only presumably had a clinically localised tumour. Men who had received endocrine therapy subsequent to radical surgery or radiotherapy most likely had tumours that had progressed after the initial treatment or had adverse prognostic findings at treatment. Those given no initial treatment probably had low-grade, clinically localised disease and were also older than the patients treated with curative intent. The initially untreated group may also have included some patients with metastatic or advanced disease without symptoms.
The response rate for the questionnaire was slightly lower for the reference group which may be owing to the fact that the majority of these men did not have any specific disease affecting the investigated functions, thereby making them less inclined to answer. The only significant difference between the reference group and the prostate cancer patients, with regard to reasons for not answering the questionnaire, was that the reference population was more difficult to locate (not living at registered address or living abroad) (Table I) . We found no indication of a lack of representativeness at least not with regard to the prevalence of diabetes and myocardial infarction since the reference population was almost identical to the general Swedish male population in this respect.
The results show that waning sexual function is the most common disease-specific reason for distress in men with prostate cancer. Urinary and bowel symptoms are more prevalent in prostate cancer patients compared with the general population but few men are severely distressed by this. The importance of an intact sexual function for the patient and the willingness to abstain from treatment that may result in waning sexual function varies greatly between patients.
